AACR 2024 | Challenges in glioblastoma treatment: bortezomib trial for improved outcomes

Martha Chekenya, PhD, University of Bergen, Bergen, Norway, discusses the challenges of treating glioblastoma, the most common malignant brain tumor in adults, with a poor prognosis of only about 15 months survival after diagnosis. Despite various targeted therapies and emerging immunotherapies, responses have been limited due to high cellular and molecular heterogeneity and the blood-brain barrier’s restrictions. Prof. Chekenya highlights a Phase I/II clinical trial (NCT03643549) using bortezomib, a proteasome inhibitor targeting the transcription factor NF-κB, to sensitize treatment-refractory glioblastoma tumors to temozolomide chemotherapy. This hypothesis-driven trial aims to overcome resistance mechanisms and improve treatment outcomes for patients. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.